US009283269B2

(12) **United States Patent**
Girsh

(10) **Patent No.: US 9,283,269 B2**
(45) **Date of Patent: Mar. 15, 2016**

(54) **METHOD FOR REDUCING THE ALLERGENICITY OF ANIMAL DANDER**

(71) Applicant: **IMMUNOPATH PROFILE, INC.**, Naples, FL (US)

(72) Inventor: **Leonard S. Girsh**, Naples, FL (US)

(73) Assignee: **IMMUNOPATH PROFILE, INC.**, Naples, FL (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/483,399**

(22) Filed: **Sep. 11, 2014**

(65) **Prior Publication Data**

US 2015/0072007 A1 Mar. 12, 2015

Related U.S. Application Data

(60) Continuation of application No. 11/592,530, filed on Nov. 2, 2006, now abandoned, which is a continuation of application No. 10/269,613, filed on Oct. 11, 2002, now abandoned, said application No. 11/592,530 is a continuation-in-part of application No. 09/611,857, filed on Jul. 7, 2000, now abandoned, which is a division of application No. 09/080,990, filed on May 19, 1998, now abandoned, which is a continuation-in-part of application No. 09/058,469, filed on Apr. 10, 1998, now abandoned, which is a continuation-in-part of application No. 09/058,430, filed on Apr. 10, 1998, now abandoned, said application No. 11/592,530 is a continuation-in-part of application No. 09/731,608, filed on Dec. 7, 2000, now abandoned, and a continuation-in-part of application No. 09/639,859, filed on Aug. 16, 2000, now Pat. No. 6,974,796.

(60) Provisional application No. 60/358,890, filed on Feb. 22, 2002, provisional application No. 60/350,119, filed on Nov. 9, 2001, provisional application No. 60/149,338, filed on Aug. 17, 1999.

(51) **Int. Cl.**

A61K 31/045	(2006.01)
A61K 31/21	(2006.01)
A61K 39/35	(2006.01)
A61K 35/20	(2006.01)
A61K 31/198	(2006.01)
A61K 31/20	(2006.01)
A61K 31/737	(2006.01)
A61K 38/39	(2006.01)
A61K 39/39	(2006.01)
A61K 39/00	(2006.01)

(52) **U.S. Cl.**

CPC ***A61K 39/35*** (2013.01); ***A61K 31/198*** (2013.01); ***A61K 31/20*** (2013.01); ***A61K 31/737*** (2013.01); ***A61K 35/20*** (2013.01); ***A61K 38/39*** (2013.01); ***A61K 39/39*** (2013.01); *A61K 2039/55511* (2013.01); *A61K 2039/55566* (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,400,199	A	9/1968	Balassa
3,917,859	A	11/1975	Terada et al.
3,920,819	A	11/1975	Stephens et al.
4,045,589	A	8/1977	Petrowski et al.
4,145,447	A	3/1979	Fisher et al.
4,196,202	A	4/1980	Okada
4,310,561	A	1/1982	Buddemeyer et al.
4,562,080	A	12/1985	Tenn
4,752,618	A	6/1988	Mascioli et al.
4,803,070	A	2/1989	Cantrell et al.
4,857,326	A	8/1989	Stitt

(Continued)

FOREIGN PATENT DOCUMENTS

WO	WO 92/21752	12/1992	
WO	WO 97/10723	3/1997	
WO	WO 0228187 A1 *	4/2002	..... A01N 59/16

OTHER PUBLICATIONS

U.S. Appl. No. 10/765,664, filed Jan. 26, 2004, Girsh.
U.S. Appl. No. 10/868,697, filed Jun. 14, 2004, Girsh.
U.S. Appl. No. 12/466,850, filed May 15, 2009, Girsh.
Henschen, A. et al. "Covalent Structure of Fibrinogen" *Annals of New York Academy of Sciences*, 1983, pp. 28-43, vol. 408.
Wayman, K.I. et al. "Neurodevelopmental outcome of young children with extrahepatic biliary atresia 1 year after liver transplantation" *The Journal of Pediatrics*, Dec. 1977, pp. 894-898, vol. 131, No. 6.

(Continued)

Primary Examiner — Robert A Wax
Assistant Examiner — Amanda Heyes
(74) *Attorney, Agent, or Firm* — Saliwanchik, Lloyd & Eisenschenk

(57) **ABSTRACT**

The present invention relates to a non-invasive medical therapy and a composition for avoiding organ transplantation, or controlling biological rejection of transplanted organs, or treating organs under consideration for replacement by transplant, and otherwise treating aged, diseased and/or abnormal tissues and/or organs. More specifically, the non-invasive medical therapy involves administering to a patient an elemental nutritional feeding comprising a free amino acid profile simulating and/or replicating a targeted diseased or transplanted tissue and/or organ. The subject invention provides methods of inactivating reactive component epitopes of moieties pathogenic substances or producing immunogenic compositions containing pathogenic substances comprising contacting pathogenic substances, or compositions containing pathogenic substances, with super critical carbon dioxide or liquid nitrogen. Similar benefits are produced using high HLB surfactants also reducing carcinogenic factors. In various embodiments, the pathogenic reactive components, epitopes, moieties or substances are inactivated and processed into immunogenic compositions. The subject invention also provides oral mucosal delivery systems for the subject therapeutic compositions and/or medications, and/or vaccines that avert the need for parenteral administration in the medical and veterinary fields.

7 Claims, 14 Drawing Sheets